Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma

Nuclear factor κB (NFκB) activation plays a crucial role in anti-apoptotic responses in response to the apoptotic signaling during tumor necrosis factor (TNFα) stimulation in Multiple Myeloma (MM). Although several drugs have been found effective for the treatment of MM by mainly inhibiting NFκB pathway, there are not any quantitative or qualitative results of comparison assessment on inhibition effect between different drugs either used alone or in combinations. Computational modeling is becoming increasingly indispensable for applied biological research mainly because it can provide strong quantitative predicting power. In this study, a novel computational pathway modeling approach is employed to comparably assess the inhibition effects of specific drugs used alone or in combinations on the NFκB pathway in MM and to predict the potential synergistic drug combinations.

[1]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[2]  Youli Zu,et al.  P38 MAPK inhibition enhancing ATO‐induced cytotoxicity against multiple myeloma cells , 2007, British journal of haematology.

[3]  B. Kholodenko,et al.  Temperature dependence of the epidermal growth factor receptor signaling network can be accounted for by a kinetic model. , 2002, Biochemistry.

[4]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[5]  Li Mao,et al.  Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells , 2022 .

[6]  Pamela K. Kreeger,et al.  Cancer systems biology: a network modeling perspective , 2009, Carcinogenesis.

[7]  R. Bresalier,et al.  The Biology of Cancer. Garland Science, Oxford, UK (2006), 864 pp. $104.95, ISBN: 0-8153-4076-1. Web site for ordering: www.garandscience.com , 2007 .

[8]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[9]  A. Bloem,et al.  Growth factors and antiapoptotic signaling pathways in multiple myeloma , 2005, Leukemia.

[10]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[11]  A. Hoffmann,et al.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. , 2002, Science.

[12]  Jacob D. Feala,et al.  Search Algorithms as a Framework for the Optimization of Drug Combinations , 2008, PLoS Comput. Biol..

[13]  Zhi-wei Li,et al.  NF-κB in the pathogenesis and treatment of multiple myeloma , 2008, Current opinion in hematology.

[14]  Igor Goryanin,et al.  Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. , 2009, Cancer research.

[15]  Robert Hooke,et al.  `` Direct Search'' Solution of Numerical and Statistical Problems , 1961, JACM.

[16]  Adam Smith,et al.  Screening for drug discovery: The leading question , 2002, Nature.

[17]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[18]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[19]  Richard Simon,et al.  In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics. , 2004, Molecular Pharmacology.

[20]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[21]  P. Richardson,et al.  The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications , 2001, Oncogene.

[22]  Paul Richardson,et al.  Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma , 2007, Clinical Cancer Research.

[23]  Kwang-Hyun Cho,et al.  The influence of the signal dynamics of activated form of IKK on NF‐κB and anti‐apoptotic gene expressions: A systems biology approach , 2006, FEBS letters.

[24]  Youli Zu,et al.  Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. , 2010, Leukemia research.

[25]  Ursula Klingmüller,et al.  Theoretical and experimental analysis links isoform- specific ERK signalling to cell fate decisions , 2009, Molecular systems biology.

[26]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[27]  D. Lauffenburger,et al.  Multipathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells , 2008, Molecular Pharmacology.